Addressing Cancer Care Disparities in Europe: Insights from the 2025 Comparator Report

By João L. Carapinha

March 27, 2025

The “Comparator Report on Cancer in Europe 2025” analyzes the landscape of cancer care across Europe. It highlights cancer care disparities persisting in different European regions and cancer types. While advances in treatment exist, many patients still struggle to access timely and effective care. Molecular diagnostics are also key for precision oncology but vary in access. Lower-income regions lack complex assays, worsening disparities in care quality.

Cancer is the world’s second-leading cause of death, with nearly 10 million deaths in 2020. The OECD’s “Health at a Glance 2023” stresses the need for better prevention and care strategies in Europe.

Rising Incidence and Reimbursement Speed

Cancer incidence in Europe rose by 58% from 1995 to 2022, reaching 3.2 million new cases yearly. Mortality rates have stabilized at 1.3-1.4 million deaths since 2008, reflecting complex factors influencing outcomes. Direct cancer treatment costs doubled from €62 billion in 1995 to €146 billion in 2023. Medicine costs now exceed 40% of total expenses, worsening access for disadvantaged groups.

Wealthier Western European countries quickly reimburse EMA-approved drugs. Meanwhile, Central and Eastern Europe face delays and restricted coverage. These cancer care disparities demand equitable policies to bridge gaps.

Implications for Health Economics and Market Access

Health Economics and Outcomes Research (HEOR) can improve cancer care access. It provides evidence to optimize resource allocation and cost-effectiveness. Frameworks like the ISPOR Value Flower could integrate societal impacts into HTA. Performance-based MEAs and multi-speed HTA processes may prioritize promising drugs while monitoring uncertain ones.

More public funding is needed for treatment optimization studies and data infrastructure. Evolving HTA methodologies should adopt a societal perspective to ensure fair access to innovative treatments.

These findings highlight the urgency of addressing cancer care disparities. HEOR can enhance equity and efficiency in healthcare. For deeper insights, explore the full report.

 

Reference url

Recent Posts

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

reserve antibiotics benefits
           

Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critical Reserve Treatment

🔍 What makes reserve antibiotics crucial in the fight against antimicrobial resistance?

The recent assessment of Meropenem/Vaborbactam by the G-BA highlights its vital role as a reserve antibiotic for severe gram-negative infections, ensuring effective treatment options when others fail. With tight regulations and stewardship in place, its designation underscores the importance of preserving these powerful tools in modern medicine.

Dive into the article to explore the implications for healthcare, economics, and patient safety.

#SyenzaNews #HealthcareInnovation #HealthEconomics

robotic surgery approval
               

NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and Address Health Inequities

🤖 Are you ready for the future of surgery?

The recent approval of 11 robotic surgery systems by NICE could improve patient care in the NHS, leading to faster recoveries and minimal invasiveness. With a focus on real-world evidence, this transformative step aims to improve health outcomes while addressing access and equity concerns.

Explore how this innovative approach will shape the landscape of surgical procedures in the coming years!

#SyenzaNews #HealthcareInnovation #MedicalDevices #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.